期刊文献+

北京地区2013~2018年替加环素不良反应回顾性分析 被引量:3

Retrospective Analysis of ADR Induced by Tigecycline in Beijing Area During 2013-2018
下载PDF
导出
摘要 目的:了解替加环素不良反应发生的特点,为临床安全使用替加环素提供参考。方法:调取国家药品不良反应(ADR)监测系统收集的2013~2018年北京地区替加环素ADR报告,对其发生的特点及相关因素进行回顾性分析。结果:统计时间内,共收到49份怀疑与替加环素有关的ADR报告。其中60岁以上老年患者居多,占67.35%;临床表现复杂多样,主要ADR累及系统为血液系统(36.21%)、消化系统(20.69%)、皮肤软组织及附件(17.24%)。ADR发生在2~6 d内占40.82%,大多经停药或对症治疗后好转。结论:临床合理使用替加环素可以减少其ADR的发生。建议在使用该药时,对患者进行严密监护,以降低发生ADR的风险。 Objective:To understand the characteristics induced by tigecycline,and to provide reference for clinical safe and rational use of tigecycline.Methods:According to the ADR reports of tigecycline collected by Beijng Center for ADR Monitoring from 2013 to 2018,the characteristics and related factors of the occurrence of tigecycline ADR were analyzed retrospectively.Results:During the statistical period,49 ADR reports suspected to be related to tigecycline were received.Of 49 ADR cases,the incidence of ADR in the elderly patients was higher than young patients,over 60 years old(67.35%).Clinical manifestations are complex and diverse.The main ADR involvement systems are blood system(36.21%),digestive system(20.69%),skin and soft tissue and accessories(17.24%).ADR occurred within 2-6 days,accounting for 40.82%.Most of them would be better after stopping drug or symptomatic treatment.Conclusion:Rational clinical use of tigecycline can reduce the incidence of ADR.It is suggested that patients should be closely monitored in order to reduce the risk of ADR.
作者 李春钰 贾自力 邢丽秋 Li Chunyu;Jia Zili;Xing Liqu(Department of Pharmacy,Beijing Fengtai Hospital,Beijing100071,China;Beijng Center for ADR Monitoring)
出处 《药物流行病学杂志》 CAS 2019年第9期581-585,共5页 Chinese Journal of Pharmacoepidemiology
关键词 替加环素 药品不良反应 报告 安全用药 Tigecycline Adverse drug reactions Report Safety medication
  • 相关文献

参考文献5

二级参考文献60

  • 1杨景勋.美国抗击病原菌对抗生素耐药的一些策略和措施[J].中国药物警戒,2004,1(2):36-37. 被引量:6
  • 2程仕虎,王睿.新一代四环素类药物替加环素的研究进展[J].科学技术与工程,2007,7(16):4123-4130. 被引量:15
  • 3Tansarli GS,Rafailidis PI,Kapaskelis A,et al.Frequency of the off-label use of antibiotics in clinical practice:a systematic review[J].Expert Rev Anti Infect Ther,2012,10(12):1383-1392.
  • 4World Medical Association.World Medical Association Declaration of Helsinki:ethical principles for medical research involving human subjects[J].JAMA,2013,310 (20):2191-2194.
  • 5Harms JM,Bartels H,Schlunzen F,et al.Antibiotics acting on the translational machinery[J].J Cell Sci,2003,116(8):1 391.
  • 6Hirata T,Nomura W,Imanishi M,et al.Effects of linking 15-zinc finger domains on DNA binding specificity and multiple DNA binding modes[J].Bioorg Med Chem Lett,2005,15(9):2 197.
  • 7FDA.Tygacil(tigecycline)for injection[EB/OL].(2013-09-30)[2015-04-05].http://www.fda.gov/Safety/MedW-atch/Safety Information/ucm228387.htm.
  • 8Bradford PA,Weaver-Sands DT,Petersen PJ.In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections[J].Clin Infect Dis,2005,41(5):S315.
  • 9Sader HS,Farrell DJ,Flamm RK,et al.Variation in potency and spectrum of tigecycline activity against bacterial strains from US medical centers since its approval for clinical use:2006-2012[J].Antimicrob Agents Ch,2014,58(4):2 274.
  • 10Gupta S,Aruna C,Nagaraj S,et al.In vitro activity of tigecycline against multidrug-resistant gram-negative blood culture isolates from critically ill patients[J].J Antimicrob Chemother,2012,67(5):1 293.

共引文献150

同被引文献38

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部